NCT03517917 is a clinical trial of Tumour tissue collection in Solid Tumor, sponsored by AstraZeneca.

Who is sponsoring NCT03517917?

NCT03517917 is sponsored by AstraZeneca.

What drugs are being tested in NCT03517917?

Interventions in NCT03517917: Tumour tissue collection.

What condition does NCT03517917 study?

NCT03517917 studies Solid Tumor.

Is NCT03517917 still recruiting?

NCT03517917 is currently completed. Last updated 23 May 2025.

Last reviewed 2025-05-23 · How we verify

NCT03517917

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Tissue Collection Research Protocol

Completed Last updated 23 May 2025

What this trial tests

trial testing Tumour tissue collection in Solid Tumor in 221 participants. Completed in 8 October 2024.

Timeline

8 February 2018

Primary endpoint
8 October 2024

8 October 2024

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	221
Start date	8 February 2018
Primary completion	8 October 2024
Estimated completion	8 October 2024
Sites	18 locations across United Kingdom, United States, Spain

Drugs / interventions tested

Tumour tissue collection

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

AstraZeneca — full company profile →

Who can join

18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-solid tumour research study which collects tumour samples from patients alongside a matched whole blood, and/or leukapheresis product for the development of manufacturing processes for potential immunotherapies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy.
Kye Y, Nagineni L, Gadad S, Ramirez F, et al · · 2022 · cited 7× · PMID 36077792 · DOI 10.3390/cancers14174255
Current status and challenges of immunotherapy in ALK rearranged NSCLC.
Qi R, Yu Y, Shen M, Lv D, et al · · 2022 · cited 6× · PMID 36591504 · DOI 10.3389/fonc.2022.1016869

Verify or expand the search:

Other trials of Tumour tissue collection

Trials testing the same drug.

NCT03419689 — Study Looking at Biomarkers in Ovarian Cancer · NA · recruiting
NCT03420118 — Study of Biomarkers in Gynecological Cancers · NA · recruiting

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03517917 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 23 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03517917.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing